Yarrow Bioscience (YARW) Asset Utilization Ratio (2018 - 2026)
Yarrow Bioscience's (YARW) quarterly Asset Utilization Ratio came in at 0.02 in Q2 2026, up 102.4% on a YoY basis from 0.01 in Q2 2025, and up 16.98% quarter-over-quarter from 0.02 in Q1 2026.
Analysis
Yarrow Bioscience (YARW) Asset Utilization Ratio (2018 - 2026) Analysis & Trends
Yarrow Bioscience (YARW) has reported Asset Utilization Ratio for 9 consecutive years, with 0.02 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Asset Utilization Ratio rose 102.4% year-over-year to 0.02; the trailing twelve-month figure through Jun 2026 stood at 0.02 (up 102.4% YoY), and the FY2025 full-year result was 0.01, up 103.07% from the prior year.
- Asset Utilization Ratio climbed to 0.02 in Q2 2026 per YARW's latest filing, from 0.02 in the prior quarter.
- Across five years, Asset Utilization Ratio topped out at 0.02 in Q2 2026 and bottomed at 0.0 in Q1 2024.
- Historically, Asset Utilization Ratio has averaged 0.01 across 5 years, with a median of 0.01 in 2022.
- The sharpest annual moves came in 2022 and 2025: Asset Utilization Ratio tumbled 91.65% in 2022, then soared 119.29% in 2025.
- Over 5 years, Asset Utilization Ratio stood at 0.01 in 2022, then tumbled by 36.28% to 0.01 in 2023, then decreased by 2.89% to 0.01 in 2024, then jumped by 42.05% to 0.01 in 2025, then jumped by 102.4% to 0.02 in 2026.
- According to Business Quant data, Asset Utilization Ratio over the past three periods registered 0.02, 0.02, and 0.01 for Q2 2026, Q1 2026, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 642.34 Bn | 621.58 Bn | 17.26 Bn | 0.49 |
| 2 | AbbVie | 446.74 Bn | 440.17 Bn | 12.70 Bn | 0.47 |
| 3 | Merck | 357.89 Bn | 350.75 Bn | 12.21 Bn | 0.52 |
| 4 | Novartis Ag | 267.44 Bn | 259.75 Bn | 11.24 Bn | 0.57 |
| 5 | Pfizer | 156.55 Bn | 144.85 Bn | 10.94 Bn | 0.31 |
| 6 | Sanofi | 52.21 Bn | 44.83 Bn | 10.79 Bn | 0.36 |
| 7 | Revolution Medicines | 42.85 Bn | 42.85 Bn | - | - |
| 8 | Incyte | 24.63 Bn | 20.09 Bn | 1.57 Bn | 0.77 |
| 9 | United Therapeutics | 21.40 Bn | 18.74 Bn | 683.80 Mn | 0.45 |
| 10 | Yarrow Bioscience | 24.16 Mn | 1.24 Mn | - | 0.02 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 0.02 |
| Mar 31, 2026 | 0.02 |
| Jun 30, 2025 | 0.01 |
| Mar 31, 2025 | 0.01 |
| Dec 31, 2024 | 0.01 |
| Sep 30, 2024 | 0.01 |
| Jun 30, 2024 | 0.01 |
| Mar 31, 2024 | 0.00 |
| Dec 31, 2023 | 0.01 |
| Sep 30, 2023 | 0.02 |
| Jun 30, 2023 | 0.01 |
| Mar 31, 2023 | 0.01 |
| Dec 31, 2022 | 0.01 |
| Sep 30, 2022 | 0.01 |
| Jun 30, 2022 | 0.01 |
| Mar 31, 2022 | 0.01 |
| Dec 31, 2021 | 0.01 |
| Sep 30, 2021 | 0.05 |
| Jun 30, 2021 | 0.06 |
| Mar 31, 2021 | 0.16 |